Back to Search Start Over

Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.

Authors :
Berek K
Paganini C
Hegen H
Bsteh G
Grams A
Auer M
Berger T
Deisenhammer F
Di Pauli F
Source :
Wiener medizinische Wochenschrift (1946) [Wien Med Wochenschr] 2022 Nov; Vol. 172 (15-16), pp. 373-378. Date of Electronic Publication: 2022 Feb 10.
Publication Year :
2022

Abstract

Background: Natalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven.<br />Case Presentation: We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.<br />Conclusion: Use of natalizumab during pregnancy may be an option in highly active multiple sclerosis.<br /> (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, ein Teil von Springer Nature.)

Details

Language :
English
ISSN :
1563-258X
Volume :
172
Issue :
15-16
Database :
MEDLINE
Journal :
Wiener medizinische Wochenschrift (1946)
Publication Type :
Academic Journal
Accession number :
35142953
Full Text :
https://doi.org/10.1007/s10354-022-00913-6